Autopsy report · NCT07349771
Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
Cause of deathFunding or business
“Sponsor declined to fund study due to inability to agree on IP.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation; Axatilimab; Biospecimen Collection; Bone Marrow Aspiration; Computed Tomography; Cyclophosphamide
- Participants
- 0
- Sites
- 3
- Countries
- United States
Trials that died the same way
- Manual Therapy/Exercises vs. Physiotherapy/Back School vs. Waiting List in Patients With Chronic Low Back Pain
“Sponsor did not want to continue the study.” - Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
“Sponsor decided not to pursue study” - Natalizumab and Chronic Inflammation
“Sponsor declined further support” - A Dose-escalation and Safety & Efficacy Study of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease
“Sponsor withdrew from the study and there was a lack of funding to complete stage 2 of the designed study.” - Evaluating Return to Continence and Potency Following Radical Prostatectomy
“The sponsor decided to not move forward with this study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.